Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes
Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes. // Endocrinology & Metabolism Clinics of North America. – URL: https://www.sciencedirect.com/science/article/pii/S0889852926000289?dgcid=rss_sd_all
Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes. Endocrinology & Metabolism Clinics of North America. https://www.sciencedirect.com/science/article/pii/S0889852926000289?dgcid=rss_sd_all
“Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes.” Endocrinology & Metabolism Clinics of North America.
@article{article44591,
title = {Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes},
journal = {Endocrinology \& Metabolism Clinics of North America},
url = {https://www.sciencedirect.com/science/article/pii/S0889852926000289?dgcid=rss_sd_all}
}